The effects of race and criminal justice involvement on access to atypical antipsychotic medications among persons with schizophrenia

Mental Health Services Research

Volumn 7, Issue 2, 2005, Pages 123-134

  Van Dorn, Richard A ^a   Swanson, Jeffrey W ^a   Swartz, Marvin S ^a   Elbogen, Eric B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Access; Arrest; Atypical; Race; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AFRICAN AMERICAN; ARTICLE; CLINICAL TRIAL; CRIMINAL JUSTICE; DISEASE SEVERITY; DRUG UTILIZATION; FEMALE; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HUMAN; INFORMATION RETRIEVAL; INTERVIEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MENTAL HEALTH SERVICE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRESCRIPTION; PROSPECTIVE STUDY; PSYCHOPHARMACOLOGY; RACE DIFFERENCE; RATING SCALE; SCHIZOPHRENIA; UNITED STATES;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIPSYCHOTIC AGENTS; COMORBIDITY; CRIMINAL LAW; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE COVERAGE; LIKELIHOOD FUNCTIONS; LOGISTIC MODELS; MALE; NORTH CAROLINA; PREJUDICE; PRISONERS; SCHIZOPHRENIA; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 19944409872     PISSN: 15223434     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11020-005-3783-z     Document Type: Article

References (74)

1. Adebimpe, V. R. (1994). Race, racism, and epidemiological surveys. Hospital and Community Psychiatry, 45, 27-31. 1:STN:280:ByuC2s7itVU%3D
2. Alegria, M., Bijl, R. V., Lin, E., Walters, E. E., & Kessler, R. C. (2000). Income differences in persons seeking outpatient treatment for mental disorders: A comparison of the United States with Ontario and The Netherlands. Archives of General Psychiatry, 57 (4), 383-391. 10.1001/ archpsyc.57.4.383
3. Alegria, M., Canino, G., Rios, R., Vera, M., Calderon, J., Rusch, D., et al. (2002). Inequalities in use of specialty mental health services among Latinos, African Americans, and non-Latino whites. Psychiatric Services, 53 (12), 1547-1555. 10.1176/appi.ps.53.12.1547
4. Austin, R. L., & Allen, M. D. (2000). Racial disparity in arrest rates as an explanation of racial disparity in commitment to Pennsylvania's prisons. Journal of Research in Crime and Delinquency, 37 (2), 200-220.
5. Baillargeon, J., & Contreras, S. A. (2001). Antipsychotic prescribing patterns in the Texas prison system. Journal of the American Academy of Psychiatry and the Law, 29 (1), 48-53. 1:STN:280:DC%2BD3MvlvFyqug%3D%3D
6. Buchanan, R. W. (1995). Clozapine: Efficacy and safety. Schizophrenia Bulletin, 21 (4), 579-591. 1:STN:280:BymA28zlvV0%3D
7. Casey, D. E. (1997). The relationship of pharmacology to side effects. Journal of Clinical Psychiatry, 58 (Suppl. 10), 55-62. 1:CAS:528:DyaK2sXls1Oku7g%3D
8. Chow, J. C.-C., Jaffee, K., & Snowden, L. (2003). Racial/ethnic disparities in the use of mental health services in poverty areas. American Journal of Public Health, 93 (5), 792-797. 12721146
9. Citrome, L., Levine, J., & Allingham, B. (1996). Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacology Bulletin, 32 (3), 321-326. 1:STN:280:ByiC387htVM%3D
10. Council of State Governments 2002 Criminal justice/mental health consensus project Council of State Governments Lexington, KY
11. Diala, C., Muntaner, C., Walrath, C., Nickerson, K. J., LaVeist, T. A., & Leaf, P. J. (2000). Racial differences in attitudes toward professional mental health care and in the use of services. American Journal of Orthopsychiatry, 70 (4), 455-464. 1:STN:280:DC%2BD3MzpsVyhug%3D%3D
12. Dimova, A. (2003). The range of therapeutic efficacy of atypical antipsychotics: A critical evaluation. Medical Hypotheses, 61 (2), 259-264. 10.1016/S0306-9877(03)00157-9
13. Ditton, P. M. (1999). Mental health and treatment of inmates and probationers (No. NCJ 174463). Washington, DC: U.S. Department of Justice, Bureau of Justice Statistics.
14. Dixon, L., Green-Paden, L., Delahanty, J., Lucksted, A., Postrado, L., & Hall, J. (2001). Variables associated with disparities in treatment of patients with schizophrenia and comorbid mood and anxiety disorders. Psychiatric Services, 52 (9), 1216-1222. 10.1176/ appi.ps.52.9.1216
15. R. E. Drake K. T. Mueser & G. J. McHugo 1996 Clinical rating scales: Alcohol Use Scale (AUS), Drug Use Scale (DUS), and Substance Abuse Treatment Scale (SATS) L. I. Sederer & B. Dickey (Eds.) Outcomes assessment in clinical practice Williams & Wilkins Baltimore, MD 113-116
16. Edens, J. F., Peters, R. H., & Hills, H. A. (1997). Treating prison inmates with co-occurring disorders: An integrative review of existing programs. Behavioral Sciences and the Law, 15 (4), 439-457. 10.1002/ (SICI)1099-0798(199723/09)15:4<439::AID-BSL282>3.0.CO;2-X
17. Eli Lilly & Company. (1999). SCAP health questionnaire. Indianapolis, IN.
18. Endicott, J., Spitzer, R., Fleiss, J., & Cohen, J. (1976). The global assessment scale: A procedure for measuring overall severity of psychiatric disturbances. Archives of General Psychiatry, 33, 766-771. 1:STN:280:CSmB3s%2Fnslw%3D
19. Fazela, S., & Danesh, J. (2002). Serious mental disorder in 23000 prisoners: A systematic review of 62 surveys. The Lancet, 359 (9306), 545-550. 10.1016/S0140-6736(02)07740-1
20. Feder, L. (1991). A comparison of the community adjustment of mentally ill offenders with those from the general prison population: An 18-month follow-up. Law and Human Behavior, 15, 477-493.
21. Feder, L. (1994). Psychiatric hospitalization history and parole decisions. Law and Human Behavior, 18, 395-410. 10.1007/BF01499047
22. Frankle, W. G., Shera, D., Berger-Hershkowitz, H., Evins, A. E., Connolly, C., Goff, D. C., et al. (2001). Clozapine-associated reduction in arrest rates of psychotic patients with criminal histories. American Journal of Psychiatry, 158 (2), 270-274. 10.1176/appi.ajp.158.2.270
23. Garb, H. N. (1997). Race bias, social class bias, and gender bias in clinical judgment. Clinical Psychology-Science and Practice, 4 (2), 99-120.
24. Glassman, A. H., & Bigger, J. T. (2001). Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. American Journal of Psychiatry, 158 (11), 1774-1782. 10.1176/appi.ajp.158.11.1774
25. Hale, A. S. (1998). A review of the safety and tolerability of sertindole. International Clinical Psychopharmacology, 13 (Suppl. 3), S65-S70. 9690973
26. Hamilton, S. H., Revicki, D. A., Genduso, L. A., & Beasley, C. M., Jr. (1998). Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology, 18 (1), 41-49. 10.1016/S0893-133X(97)00111-5
27. Hammett, T. M., Roberts, C., & Kennedy, S. (2001). Health-related issues in prisoner reentry. Crime and Delinquency, 47 (3), 390-409.
28. Haywood, T. W., Kravitz, H. M., Grossman, L. S., Cavanaugh, J. L., Davis, J. M., & Lewis, D. A. (1995). Predicting the revolving-door phenomenon among patients with schizophrenic, schizoaffective, and affective-disorders. American Journal of Psychiatry, 152 (6), 856-861. 1:STN:280:ByqB2svnsV0%3D
29. Henderson, D. C. (2002). Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence? CNS Drugs, 16 (2), 77-89. 1:CAS:528:DC%2BD38XitValsbc%3D
30. Hoptman, M. J., Yates, K. F., Patalinjug, M. B., Wack, R. C., & Convit, A. (1999). Clinical prediction of assaultive behavior among male psychiatric patients at a maximum-security forensic facility. Psychiatric Services, 50 (11), 1461-1466. 1:STN:280:DC%2BD3c%2FhtFGrsA%3D%3D
31. Horner, R. D., Swanson, J. W., Bosworth, H. B., & Matchar, D. B. (2003). Effects of race and poverty on the process and outcome of inpatient rehabilitation services among stroke patients. Stroke, 34, 1027-1031. 10.1161/01.STR.0000060028.60365.5D
32. Jacoby, J. E., & Kozie-Peak, B. (1997). The benefits of social support for mentally ill offenders: Prison to community transitions. Behavioral Sciences and the Law, 15, 483-501. 10.1002/ (SICI)1099-0798(199723/09)15:4<483::AID-BSL280>3.0.CO;2-F
33. Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45 (9), 789-796. 1:STN:280:BieA38rotFc%3D
34. S. J. Keith D. A. Regier D. S. Rae 1991 Schizophrenic disorders In L. N. Robins & D. A. Regier (Eds.) Psychiatric disorders in the America: The Epidemiologic Catchment Area Study Free Press New York 33-52
35. Kendler, K. S., Gallagher, T. J., Abelson, J. M., & Kessler, R. C. (1996). Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: The National Comorbidity Survey. Archives of General Psychiatry, 53, 1022-1031. 1:STN:280:ByiD28jovFM%3D
36. Koro, C. E., Fedder, D. O., L'Italien, G., Weiss, S., Magder, L. S., Kreyenbuhl, J., et al. (2002a). An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Archives of General Psychiatry, 59 (11), 1021-1026. 10.1001/archpsyc.59.11.1021
37. Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S. S., Magder, L. S., Kreyenbuhl, J., et al. (2002b). Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population based nested case - control study. British Medical Journal, 325 (7358), 243-245. 1:CAS:528:DC%2BD38XmslOkt78%3D
38. Kressin, N. R., & Petersen, L. A. (2001). Racial differences in the use of invasive cardiovascular procedures: Review of the literature and prescription for future research. Annals of Internal Medicine, 135 (5), 352-366. 1:STN:280:DC%2BD3MrgsFKjug%3D%3D
39. Kuno, E., & Rothbard, A. B. (2002). Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. American Journal of Psychiatry, 159 (4), 567-572. 10.1176/ appi.ajp.159.4.567
40. Lawson, W. B. (1996). Clinical issues in the pharmacotherapy of African Americans. Psychopharmacology Bulletin, 32, 275-279. 1:STN:280:BymA2sfivFU%3D
41. Lehman, A. F., & Steinwachs, D. M. (1998). Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) client survey. Schizophrenia Bulletin, 24 (1), 11-20. 1:STN:280:DyaK1c7mtFKnuw%3D%3D
42. Lieberman, J. A. (1996). Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis. Journal of Clinical Psychiatry, 57 (Suppl. 11), 68-71. 1:CAS:528:DyaK28XnsValsbY%3D
43. Mark, T. L., Dirani, R., Slade, E., & Russo, P. A. (2002). Access to new medications to treat schizophrenia. Journal of Behavioral Health Services and Research, 29 (1), 15-29.
44. Mark, T. L., Palmer, L. A., Russo, P. A., & Vasey, J. (2003). Examination of treatment pattern differences by race. Mental Health Services Research, 5 (4), 241-250. 10.1023/A:1026281118990
45. Moore, N. A. (1999). Behavioural pharmacology of the new generation of antipsychotic agents. British Journal of Psychiatry, 174 (Suppl. 38), 5-11.
46. Morgan, D. W., Edwards, A. C., & Faulkner, L. R. (1993). The adaptation to prison by individuals with schizophrenia. Bulletin of the American Academy of Psychiatry and the Law, 21 (4), 427-433. 1:STN:280:ByuA3s7ns1w%3D
47. Morrissey, J. P., Swanson, J. W., Goldstrom, I., & Manderscheid, R. W. (1993). Overview of mental health services provided by state adult correctional facilities: United States, 1988. Mental Health Statistical Note, 207, 1-13. 8332075
48. Neighbors, H. W., Jackson, J. S., Campbell, L., & Williams, D. (1989). The influence of racial factors on psychiatric diagnosis: A review and suggestions for research. Community Mental Health Journal, 25 (4), 301-311. 10.1007/BF00755677
49. Nelson, K., Norris, K., & Mangione, C. M. (2002). Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: Data from the Third National Health and Nutrition Examination Survey. Archives of Internal Medicine, 162 (8), 929-935. 10.1001/archinte.162.8.929
50. Padgett, D., Patrick, C., Burns, B., & Schlesinger, H. (1994). Ethnicity and the use of outpatient mental health services in a national insured population. American Journal of Public Health, 84 (2), 222-226. 1:STN:280:ByuC38jmtlQ%3D
51. Pescosolido, B. A., Monahan, J., Link, B. G., Stueve, A., & Kikuzawa, S. (1999). The public's view of the competence, dangerousness, and need for legal coercion of persons with mental health problems. American Journal of Public Health, 89 (9), 1339-1345. 1:STN:280:DyaK1MvgtlOqug%3D%3D
52. Potvin, S., Stip, E., & Roy, J. Y. (2003). Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: Towards testable hypotheses. International Clinical Psychopharmacology, 18 (3), 121-132. 10.1097/00004850-200305000-00001
53. Price, N., Glazer, W., & Morgenstern, H. (1985). Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients. American Journal of Psychiatry, 142 (12), 1491-1492. 1:STN:280:BimD2svmt1Y%3D
54. Revicki, D. A., Genduso, L. A., Hamilton, S. H., Ganoczy, D., & Beasley, C. M., Jr. (1999). Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial. Quality of Life Research, 8 (5), 417-426. 10.1023/A:1008958925848
55. Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., et al. (1997). A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New England Journal of Medicine, 337 (12), 809-815. 10.1056/NEJM199709183371202
56. Sampson, R. J., & Lauritsen, J. L. (1997). Racial and ethnic disparities in crime and criminal justice in the United States. Ethnicity, Crime, and Immigration, 21, 311-374.
57. Segal, S. P., Bola, J. R., & Watson, M. A. (1996). Race, quality of care and antipsychotic prescribing practices in psychiatric emergency services. Psychiatric Services, 47 (3), 282-286. 1:STN:280:BymH3Mjns1U%3D
58. Sheitman, B. B., Lee, H., Strauss, R., & Lieberman, J. A. (1997). The evaluation and treatment of first-episode psychosis. Schizophrenia Bulletin, 23 (4), 653-661. 1:STN:280:DyaK1c%2Fjt1Ojtw%3D%3D
59. Shore, D. (1998). Editorial: Recent developments in atypical antipsychotic medications. Schizophrenia Bulletin, 24 (1), 33. 1:STN:280:DyaK1c7mtFKmsg%3D%3D
60. Smelson, D. A., Losonczy, M. F., Davis, C. W., Kaune, M., Williams, J., & Ziedonis, D. (2002). Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Canadian Journal of Psychiatry, 47 (7), 671-675.
61. Steadman, H. J., Fabisiak, S., Dvoskin, J., & Holohean, E. J., Jr. (1987). A survey of mental disability among state prison inmates. Hospital and Community Psychiatry, 38 (10), 1086-1090. 1:STN:280:BieD3s7itF0%3D
62. Swanson, J. W., Borum, R., Swartz, M. S., & Hiday, V. (1999). Violent behavior preceding hospitalization among persons with severe mental illness. Law and Human Behavior, 23 (2), 185-204. 10.1023/ A:1022320918171
63. Swanson, J. W., Estroff, S., Swartz, M. S., Borum, R., Lachicotte, W., Zimmer, C., et al. (1997). Violence and severe mental disorder in clinical and community populations: The effects of psychotic symptoms, comorbidity, and lack of treatment. Psychiatry, 60 (1), 1-22. 1:STN:280:ByiB2snlsFw%3D
64. Swanson, J. W. (2001). Correctional mental health in North Carolina: An expensive non-solution. The Journal of Common Sense, 6 (3).
65. Swanson, J. W., Swartz, M. S., Borum, R., Hiday, V. A., Wagner, H. R., & Burns, B. J. (2000). Involuntary out-patient commitment and reduction of violent behaviour in persons with severe mental illness. British Journal of Psychiatry, 176, 324-331. 10.1192/bjp.176.4.324
66. Swanson, J. W., Swartz, M. S., & Elbogen, E. B. (2004). Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophrenia Bulletin, 30 (1), 3-20. 15176758
67. Takeuchi, D. T., & Williams, D. R. (2003). Race, ethnicity and mental health: Introduction to the special issue. Journal of Health and Social Behavior, 44 (3), 233-236.
68. Teplin, L. A. (1990a). Detecting disorder: The treatment of mental illness among jail detainees. Journal of Consulting and Clinical Psychology, 58 (2), 233-236. 10.1037//0022-006X.58.2.233
69. Teplin, L. A. (1990b). The prevalence of severe mental disorder among male urban jail detainees: Comparison with the Epidemiologic Catchment Area Program. American Journal of Public Health, 80 (6), 663-669. 1:STN:280:By%2BB287otVw%3D
70. Teplin, L. A., Abram, K. M., & McClelland, G. M. (1997). Mentally disordered women in jail: Who receives services? American Journal of Public Health, 87 (4), 604-609. 1:STN:280:ByiB1M7ovF0%3D
71. Tollefson, G. D., Beasley, C. M., Jr., Tran, P. V., Street, J. S., Krueger, J. A., Tamura, R. N., et al. (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. American Journal of Psychiatry, 154 (4), 457-465. 1:STN:280:ByiB2crms1c%3D
72. Turner, B. J., Cunningham, W. E., Duan, N., Andersen, R. M., Shapiro, M. F., Bozzette, S. A., et al. (2000). Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Archives of Internal Medicine, 160 (17), 2614-2622. 10.1001/archinte.160.17.2614
73. B. M. Veysey 1994 Challenges for the future U.S. Department of Justice, National Institute of Corrections Washington, DC
74. R. Walmsley 2000 World prison population list (No. 88) Home Office Research London